Laura Chico
Stock Analyst at Wedbush
(2.12)
# 2,986
Out of 4,840 analysts
220
Total ratings
33.78%
Success rate
-3.66%
Average return
Main Sectors:
Stocks Rated by Laura Chico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VIGL Vigil Neuroscience | Downgrades: Neutral | $13 → $8 | $7.88 | +1.52% | 11 | May 22, 2025 | |
| TVTX Travere Therapeutics | Reiterates: Outperform | $30 | $15.34 | +95.57% | 11 | May 16, 2025 | |
| GOSS Gossamer Bio | Reiterates: Outperform | $4 | $1.12 | +257.14% | 5 | May 16, 2025 | |
| SLDB Solid Biosciences | Maintains: Outperform | $18 → $17 | $3.04 | +459.21% | 2 | May 16, 2025 | |
| JBIO Jade Biosciences | Reiterates: Outperform | $17 | $7.34 | +131.61% | 2 | May 15, 2025 | |
| ANRO Alto Neuroscience | Reiterates: Neutral | $4 | $2.87 | +39.37% | 4 | May 15, 2025 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $32 → $30 | $13.21 | +127.10% | 8 | May 7, 2025 | |
| VERA Vera Therapeutics | Maintains: Neutral | $34 → $26 | $19.04 | +36.55% | 8 | May 7, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Underperform | $26 → $28 | $36.10 | -22.44% | 7 | May 5, 2025 | |
| EWTX Edgewise Therapeutics | Maintains: Outperform | $43 | $14.33 | +200.17% | 10 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $43 | $15.50 | +177.42% | 2 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $3 | $0.29 | +929.51% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $36 | $17.93 | +100.78% | 6 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $28 | $4.09 | +584.60% | 9 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $29 | $16.89 | +71.70% | 14 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $6 | $6.52 | -7.98% | 9 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $157 → $147 | $122.64 | +19.86% | 9 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $46 → $48 | $35.08 | +36.83% | 12 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $12 | $1.47 | +716.33% | 10 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $1.83 | +1,102.19% | 1 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $210 → $205 | $128.39 | +59.67% | 16 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $49 | $29.46 | +66.33% | 8 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $7 | $2.82 | +148.23% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $3.97 | +177.08% | 13 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $42 | $13.94 | +201.40% | 7 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $17 | $9.18 | +85.19% | 6 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $31 | $15.98 | +93.99% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $11 | $0.32 | +3,337.50% | 4 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $3.86 | +29.53% | 5 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $58.11 | - | 5 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $2.61 | +91.94% | 2 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $149 | $15.34 | +868.06% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $720 | $7.36 | +9,682.61% | 1 | Jan 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Strong Buy | $280 | $24.00 | +1,066.67% | 1 | Apr 21, 2017 |
Vigil Neuroscience
May 22, 2025
Downgrades: Neutral
Price Target: $13 → $8
Current: $7.88
Upside: +1.52%
Travere Therapeutics
May 16, 2025
Reiterates: Outperform
Price Target: $30
Current: $15.34
Upside: +95.57%
Gossamer Bio
May 16, 2025
Reiterates: Outperform
Price Target: $4
Current: $1.12
Upside: +257.14%
Solid Biosciences
May 16, 2025
Maintains: Outperform
Price Target: $18 → $17
Current: $3.04
Upside: +459.21%
Jade Biosciences
May 15, 2025
Reiterates: Outperform
Price Target: $17
Current: $7.34
Upside: +131.61%
Alto Neuroscience
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $2.87
Upside: +39.37%
Denali Therapeutics
May 7, 2025
Maintains: Outperform
Price Target: $32 → $30
Current: $13.21
Upside: +127.10%
Vera Therapeutics
May 7, 2025
Maintains: Neutral
Price Target: $34 → $26
Current: $19.04
Upside: +36.55%
Praxis Precision Medicines
May 5, 2025
Maintains: Underperform
Price Target: $26 → $28
Current: $36.10
Upside: -22.44%
Edgewise Therapeutics
Apr 21, 2025
Maintains: Outperform
Price Target: $43
Current: $14.33
Upside: +200.17%
Mar 14, 2025
Maintains: Outperform
Price Target: $42 → $43
Current: $15.50
Upside: +177.42%
Mar 12, 2025
Maintains: Outperform
Price Target: $4 → $3
Current: $0.29
Upside: +929.51%
Mar 12, 2025
Reiterates: Outperform
Price Target: $36
Current: $17.93
Upside: +100.78%
Mar 12, 2025
Maintains: Outperform
Price Target: $27 → $28
Current: $4.09
Upside: +584.60%
Mar 3, 2025
Maintains: Neutral
Price Target: $30 → $29
Current: $16.89
Upside: +71.70%
Feb 12, 2025
Reiterates: Neutral
Price Target: $6
Current: $6.52
Upside: -7.98%
Feb 7, 2025
Maintains: Outperform
Price Target: $157 → $147
Current: $122.64
Upside: +19.86%
Jan 13, 2025
Reiterates: Neutral
Price Target: $46 → $48
Current: $35.08
Upside: +36.83%
Nov 8, 2024
Maintains: Outperform
Price Target: $19 → $12
Current: $1.47
Upside: +716.33%
Oct 3, 2024
Initiates: Outperform
Price Target: $22
Current: $1.83
Upside: +1,102.19%
Sep 23, 2024
Maintains: Neutral
Price Target: $210 → $205
Current: $128.39
Upside: +59.67%
Aug 9, 2024
Maintains: Outperform
Price Target: $50 → $49
Current: $29.46
Upside: +66.33%
Aug 7, 2024
Maintains: Neutral
Price Target: $8 → $7
Current: $2.82
Upside: +148.23%
Aug 2, 2024
Reiterates: Outperform
Price Target: $11
Current: $3.97
Upside: +177.08%
Jul 29, 2024
Reiterates: Outperform
Price Target: $42
Current: $13.94
Upside: +201.40%
Jul 11, 2024
Reiterates: Outperform
Price Target: $17
Current: $9.18
Upside: +85.19%
May 9, 2024
Maintains: Outperform
Price Target: $35 → $31
Current: $15.98
Upside: +93.99%
Apr 11, 2024
Maintains: Outperform
Price Target: $13 → $11
Current: $0.32
Upside: +3,337.50%
Mar 20, 2024
Reiterates: Neutral
Price Target: $5
Current: $3.86
Upside: +29.53%
Sep 28, 2023
Initiates: Market Perform
Price Target: n/a
Current: $58.11
Upside: -
Aug 12, 2022
Maintains: Outperform
Price Target: $9 → $5
Current: $2.61
Upside: +91.94%
Aug 8, 2022
Downgrades: Neutral
Price Target: $149
Current: $15.34
Upside: +868.06%
Jan 19, 2018
Initiates: Outperform
Price Target: $720
Current: $7.36
Upside: +9,682.61%
Apr 21, 2017
Initiates: Strong Buy
Price Target: $280
Current: $24.00
Upside: +1,066.67%